Dr. Serafini is a co-founder of Atreca. Before founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was co-founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.
Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University, and he performed postdoctoral research at the University of California, San Francisco.
Susan Berland has over 20 years of experience in diverse areas of financial management and business transactions. Her senior management experience has included the position of Chief Financial Officer for Mendel Biotechnology and Poniard Pharmaceuticals. She was earlier in her career Director in Monsanto’s corporate M&A group, and she subsequently led that company’s financial planning function through their merger with Pharmacia & Upjohn. She has worked in a variety of industries including life sciences (pharmaceuticals, molecular diagnostics, and medical devices), agriculture (seed operations, biotechnology, and crop protection), and telecommunications.
Ms. Berland holds MBA and BBA degrees from the University of Wisconsin – Milwaukee.
Dr. Cavet is a co-founder of Atreca. He previously led informatics and computational biology at multiple biotechnology and information technology companies, including as a vice president at Crescendo Bioscience, where he was instrumental in developing Vectra® DA, their marketed diagnostic product.
Prior to Atreca, Dr. Cavet was Chief Information Officer and Head of Computational Sciences at Nodality. He has also led informatics and computational biology teams at Genentech, Merck, and Rosetta Inpharmatics. Dr. Cavet received BS and PhD degrees in Biochemistry from Cambridge University, and he performed postdoctoral research at Stanford University.
Mrs. Dillon is a co-founder of Atreca. Prior to her role at Atreca, Mrs. Dillon served sequentially as the chief business officer of Nuon Therapeutics, Anacor, Avidia, and Celera Genomics, and held previous positions including vice president at Exelixis and Hoffmann-La Roche, and senior marketing and sales management positions at Syntex. Mrs. Dillon received a BS from the University of California, Los Angeles.
Dr. Emerling is a co-founder of Atreca. Prior to founding Atreca, he was Senior Director of Pharmacology at Nuon Therapeutics, a development-stage biopharmaceutical company. Previously, Dr. Emerling was Senior Director of Preclinical Pharmacology at Renovis (and then at Evotec, its acquirer), which he joined as its first scientist.
Dr. Emerling received a BA in biochemistry from the University of California, Berkeley, and a PhD in neurobiology from the Massachusetts Institute of Technology, and he performed postdoctoral research at the University of California, Berkeley.
Dr. Greenberg was previously Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals, where he helped bring innovative immuno-oncology combinations to the clinic. Prior to Checkmate, Dr. Greenberg was Vice President of Global Research, Oncology, at MedImmune (AstraZeneca), where he spearheaded global research activities for immune-mediated and tumor-targeted therapies, a number of which are advancing in the clinic. He previously had served as Senior Director of Research, Oncology, at Pfizer, as a Full Member at the Fred Hutchinson Cancer Research Center in Seattle, and as a tenured Associate Professor at Baylor College of Medicine in Houston.
Dr. Greenberg received a BSc in microbiology and immunology from the University of Toronto and a PhD in microbiology and immunology from the University of British Columbia. He performed postdoctoral research at Baylor College of Medicine in Houston.
Mr. Ray has over twenty-five years of transactions, commercial operations, and marketing experience in pharmaceutical and biotechnology companies. Prior to Atreca, Mr. Ray was Vice President of Global Licensing at Aptalis Pharmaceuticals. Previously, Mr. Ray led business development at AcelRx Pharmaceuticals, Limerick Biopharma, and DURECT, and he led marketing at ALZA.
Mr. Ray received a BA in human biology from Stanford University and an MBA from the Anderson School of Business at the University of California, Los Angeles.
Dr. Volkmuth is a co-founder of Atreca. Prior to founding Atreca, he was co-founder and President of Innectus, a provider of informatics software and services to emerging life sciences companies. Before leading Innectus, Dr. Volkmuth was Senior Director of Informatics and Information Technology at Renovis (and then at Evotec, its acquirer), which he joined as a startup.
Previously, he held research positions at Incyte and Ceres. Dr. Volkmuth received twin BS degrees in mathematics and physics from the University of Minnesota and MA and PhD degrees in physics from Princeton University, and he performed postdoctoral research at Stanford University.
Dr. Woo is a co-founder of Atreca. Prior to Atreca, he was an independent consultant to the biotechnology industry. Dr. Woo has held management positions of increasing responsibility at Bristol-Myers Squibb, Johnson & Johnson, Celera Genomics, and Avidia. Before entering the biotechnology industry, Dr. Woo was a management consultant with Mitchell Madison Group.
Dr. Woo received a BA in biochemistry from the University of California, Berkeley,a PhD in chemistry from Northwestern University, and he performed postdoctoral research at Memorial Sloan-Kettering Cancer Center.